A Phase I Study to Evaluate the Safety and Pharmacokinetics of TQB3824 in Subjects With Advanced Cancer
Latest Information Update: 23 Sep 2021
Price :
$35 *
At a glance
- Drugs TQB 3824 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Sep 2021 New trial record